Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials
Introduction The type of extended adjuvant endocrine therapy is not clear, nor is the optimum duration of extended adjuvant endocrine therapy for patients with early breast cancer. Our study aims to satisfy the requirements for systematically identifying and synthesising the available evidence on th...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-04-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/13/4/e070972.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166259724451840 |
|---|---|
| author | Qingfeng Wang Qiancheng Hu Ting Luo Daoli Ye Zhao Xudong Hongfeng Gou |
| author_facet | Qingfeng Wang Qiancheng Hu Ting Luo Daoli Ye Zhao Xudong Hongfeng Gou |
| author_sort | Qingfeng Wang |
| collection | DOAJ |
| description | Introduction The type of extended adjuvant endocrine therapy is not clear, nor is the optimum duration of extended adjuvant endocrine therapy for patients with early breast cancer. Our study aims to satisfy the requirements for systematically identifying and synthesising the available evidence on the clinical safety and efficacy of extended adjuvant endocrine therapy for patients with hormone receptor-positive early breast cancer.Methods and analysis A comprehensive electronic literature database search will be performed using three electronic databases: PubMed, Cochrane Library and Embase (Ovid interface). Our main outcomes of interest were overall survival, disease-free survival, relapse-free survival, invasive contralateral breast cancer, acceptability and grades 3 and 4 non-haematological toxicities in this study. We will assess the risk of bias and overall quality of evidence using the Cochrane Collaboration’s tool and Grades of Recommendation, Assessment, Development and Evaluation, respectively. We will perform subgroup and sensitivity analyses in the selected trials. We will assess the three key assumptions of network meta-analysis: transitivity, consistency and homogeneity.Ethics and dissemination The protocol was preregistered in the International Prospective Register of Systematic Reviews (PROSPERO) database. Ethics approval and patient consent are not required for the network meta-analysis. The final results of this network meta-analysis will be disseminated through national and international conferences and published in a peer-reviewed journal.PROSPERO registration number CRD42021278271. |
| format | Article |
| id | doaj-art-478f270594e34b518441418c86f6fe88 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2023-04-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-478f270594e34b518441418c86f6fe882024-11-15T20:50:12ZengBMJ Publishing GroupBMJ Open2044-60552023-04-0113410.1136/bmjopen-2022-070972Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trialsQingfeng Wang0Qiancheng Hu1Ting Luo2Daoli Ye3Zhao Xudong4Hongfeng Gou51 Department of Abdominal Oncology, Cancer Center, Sichuan University West China Hospital, Chengdu, Sichuan, China1 Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaMulti-omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaGastric Cancer Center, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, ChinaLaboratory of Animal Tumor Models, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China1 Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, ChinaIntroduction The type of extended adjuvant endocrine therapy is not clear, nor is the optimum duration of extended adjuvant endocrine therapy for patients with early breast cancer. Our study aims to satisfy the requirements for systematically identifying and synthesising the available evidence on the clinical safety and efficacy of extended adjuvant endocrine therapy for patients with hormone receptor-positive early breast cancer.Methods and analysis A comprehensive electronic literature database search will be performed using three electronic databases: PubMed, Cochrane Library and Embase (Ovid interface). Our main outcomes of interest were overall survival, disease-free survival, relapse-free survival, invasive contralateral breast cancer, acceptability and grades 3 and 4 non-haematological toxicities in this study. We will assess the risk of bias and overall quality of evidence using the Cochrane Collaboration’s tool and Grades of Recommendation, Assessment, Development and Evaluation, respectively. We will perform subgroup and sensitivity analyses in the selected trials. We will assess the three key assumptions of network meta-analysis: transitivity, consistency and homogeneity.Ethics and dissemination The protocol was preregistered in the International Prospective Register of Systematic Reviews (PROSPERO) database. Ethics approval and patient consent are not required for the network meta-analysis. The final results of this network meta-analysis will be disseminated through national and international conferences and published in a peer-reviewed journal.PROSPERO registration number CRD42021278271.https://bmjopen.bmj.com/content/13/4/e070972.full |
| spellingShingle | Qingfeng Wang Qiancheng Hu Ting Luo Daoli Ye Zhao Xudong Hongfeng Gou Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials BMJ Open |
| title | Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials |
| title_full | Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials |
| title_fullStr | Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials |
| title_full_unstemmed | Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials |
| title_short | Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials |
| title_sort | optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor positive breast cancer protocol for a network meta analysis of randomised controlled trials |
| url | https://bmjopen.bmj.com/content/13/4/e070972.full |
| work_keys_str_mv | AT qingfengwang optimumdurationofextendedadjuvantendocrinetherapyinpatientswithhormonereceptorpositivebreastcancerprotocolforanetworkmetaanalysisofrandomisedcontrolledtrials AT qianchenghu optimumdurationofextendedadjuvantendocrinetherapyinpatientswithhormonereceptorpositivebreastcancerprotocolforanetworkmetaanalysisofrandomisedcontrolledtrials AT tingluo optimumdurationofextendedadjuvantendocrinetherapyinpatientswithhormonereceptorpositivebreastcancerprotocolforanetworkmetaanalysisofrandomisedcontrolledtrials AT daoliye optimumdurationofextendedadjuvantendocrinetherapyinpatientswithhormonereceptorpositivebreastcancerprotocolforanetworkmetaanalysisofrandomisedcontrolledtrials AT zhaoxudong optimumdurationofextendedadjuvantendocrinetherapyinpatientswithhormonereceptorpositivebreastcancerprotocolforanetworkmetaanalysisofrandomisedcontrolledtrials AT hongfenggou optimumdurationofextendedadjuvantendocrinetherapyinpatientswithhormonereceptorpositivebreastcancerprotocolforanetworkmetaanalysisofrandomisedcontrolledtrials |